On February 26, Gelonghui Pharmaceutical (002393.SZ) announced its 2023 annual performance report. In 2023, the company achieved total operating revenue of 1.153 billion yuan, an increase of 0.56% over the same period last year. Achieved operating profit of 420 million yuan, an increase of 255.73% over the same period of the previous year; realized total profit of 420 million yuan, an increase of 255.17% over the same period of the previous year; realized net profit attributable to shareholders of listed companies of 362 million yuan, an increase of 286.47% over the same period of the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 149.6 million yuan, an increase of 20.27% over the previous year; and basic earnings per share.
力生制药(002393.SZ)业绩快报：2023年度归母净利润3.62亿元 同比增加286.47%
Lisheng Pharmaceutical (002393.SZ) Performance Report: Net profit of 362 million yuan in 2023 increased 286.47% year-on-year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.